Diffuse Large B-Cell Lymphoma Unclassifiable

Diffuse Large B-Cell Lymphoma Unclassifiable — Trials · CancerIndex

Clinical trials

Registered studies

17 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 11
Recruiting: 6
Ph III recruiting: 0
Growth YoY: —
Industry share: 18%
Top sponsor: National Cancer Institute (NCI)
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (3)

clinicaltrialsPublishedShowing 1–3 of 3 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT04665765	Polatuzumab Vedotin, Rituximab, Ifosfamide, Carboplatin, and Etoposide (PolaR-ICE) as Initial Salvage Therapy for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma	active not recruiting	Phase 2	41	City of Hope Medical CenterOTHER	1	Sep 11, 2026	clinicaltrials
NCT04799275	Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma	active not recruiting	Phase 2 / Phase 3	422	National Cancer Institute (NCI)NIH